The Delhi High court has directed US-based pharma giant Eli Lilly to approach intellectual property tribunal IPAB to resolve its dispute with Ranbaxy over patents for ‘Tetracyclic Derivatives’, a group of chemical compounds having wide-ranging medical applications.

Justice S Muralidhar directed the Intellectual Property Appellate Board to consider the application filed by Eli Lilly & Co against the Controller of the Patent and Design which had rejected its claim following Ranbaxy’s opposition.

“If the appeal before IPAB is filed by Eli Lilly & Co within a period of two weeks …IPAB will consider and decide such application,” the court said declining to excercise its jurisdiction over the pharma major’s plea.

The court said “all contentions of both Eli Lilly & Co and Ranbaxy are left open to be urged before IPAB which will be dealt with such contentions in accordance law”.

Post to Twitter Tweet This Post

  • Share/Bookmark

You may also want to read these

  1. Taro tells its shareholders to keep Sun Pharma bid at bay
  2. Ranbaxy Christmas Surprise : FDA Again Warns Disaster-Prone Company
  3. Ranbaxy sells entire stake in chinese joint venture
  4. Property tax goes up 5%, professional tax comes in
  5. SEBI asks US authorities not to take action against Satyam